Nonmyeloablative stem cell transplantation for solid tumors: expanding the application of allogeneic immunotherapy.
In the arena of tumor immunology, there is a growing perception that the graft-versus-leukemia (GVL) reaction that follows allogeneic stem cell transplantation represents the most potent form of cancer immunotherapy currently in clinical use. While allogeneic stem cell transplantation has become an accepted form of "immunotherapy" for the treatment of hematological malignancies, its efficacy in inducing antitumor effects against nonhematological cancers has, until recently, been largely unexplored. The investigational application of nonmyeloablative allogeneic stem cell transplantation (NST) in solid tumors represents the logical consequence of almost 50 years of experimental and clinical research into the immunological basis for the cure of hematological malignancies following allogeneic bone marrow transplant (BMT). Here we review the historical background, development, and preliminary clinical results of allogeneic stem cell transplantation as immunotherapy for solid tumors.
Childs
Richard
R
Stem Cell Transplant Unit, Hematology Branch, National Heart, Lung and Blood Insitute, National Institutes of Health, Bethesda, MD 20892, USA.
Barrett
John
J
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000592:standards / Q000633:toxicity; D002985:Clinical Protocols; D020350:Graft vs Tumor Effect; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D009369:Neoplasms / Q000628:therapy*; D019172:Transplantation Conditioning / Q000379:methods* / Q000592:standards; D014184:Transplantation, Homologous / Q000276:immunology